Ocumension Therapeutics announced an agreement with Alcon under which Ocumension will acquire or secure commercialization rights in China to a portfolio of Alcon’s dry eye treatments and procedural drops, including established products and one in the development stage. The agreement also encompasses research and development, manufacturing, and commercialization efforts within China.

The agreement grants Ocumension outright ownership in China of several products, including Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl. Additionally, Ocumension will acquire the commercialization rights in China for Systane Ultra and AR-15512. Following a transition period, Ocumension will take over manufacturing of the acquired products for the Chinese market and will also be responsible for developing, manufacturing, and commercializing AR-15512 in China.